Pacira BioSciences reported a 5% revenue increase to $177.4 million in Q1 2026, driven by growth in its commercial portfolio including EXPAREL and ZILRETTA products. The company completed enrollment in a Phase 3 study for ZILRETTA targeting shoulder osteoarthritis pain, with topline results expected by year-end. Pacira also highlighted real-world data supporting EXPAREL's cost-effectiveness and reduced opioid use in orthopedic procedures. The company reiterated full-year 2026 guidance, aiming for total revenues between $745 million and $770 million, and continues to focus on its 5x30 strategy to drive growth and innovation in non-opioid pain treatments.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
